Assenagon Asset Management S.A. Mersana Therapeutics, Inc. Transaction History

Assenagon Asset Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$3.74 - $6.63 $4.02 Million - $7.12 Million	-1,073,748 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$5.48 - $9.86 $930,953 - $1.68 Million	169,882 Added 18.8%	1,073,748 $6.68 Million
Q3 2021 Oct 19, 2021	SELL	$8.56 - $14.47 $1.17 Million - $1.98 Million	-137,076 Reduced 13.17%	903,866 $8.52 Million
Q2 2021 Jul 15, 2021	BUY	$13.28 - $18.07 $13.8 Million - $18.8 Million	1,040,942 New	1,040,942 $14.1 Million
Q1 2020 Apr 17, 2020	SELL	$4.41 - $9.28 $151,148 - $318,062	-34,274 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$1.45 - $6.73 $49,697 - $230,664	34,274 New	34,274 $196,000
Q3 2019 Oct 16, 2019	SELL	$1.54 - $4.2 $201,124 - $548,520	-130,600 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$3.84 - $6.4 $501,504 - $835,840	130,600 New	130,600 $529,000

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $59.3M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.